Enzyre

About Enzyre

Enzyre B.V. operates as a diagnostics firm focused on developing solutions for personalized medicine, specifically in the area of blood coagulation. A spin-off from the Radboud University Medical Center in the Netherlands, the company was co-founded in 2016 by Waander van Heerde and Guido Maertens. Waander van Heerde, the Chief Scientific Officer, possesses over three decades of expertise in coagulation and previously established another spin-off company. His extensive background includes a PhD in the Biochemistry of Thrombosis and Hemostasis from Utrecht University and numerous leadership roles in hemostasis research at Radboudumc. Guido Maertens served as CEO from the company's inception until late 2023, leading it through significant growth phases, including a major financing round and strategic partnerships. His experience spans finance and management across the biotechnology and healthcare sectors.

The company's core business revolves around its proprietary point-of-care (POC) diagnostic platform, designed to measure a variety of enzymatic reactions from a small blood sample using chemiluminescence. The primary market for this technology is individuals with bleeding disorders, such as hemophilia, who require frequent monitoring of their coagulation status to manage their therapy effectively. Enzyre's business model centers on the sale of a portable diagnostic system, which includes a reusable processing unit and single-use microfluidic cartridges. The company has also established strategic partnerships, notably with Takeda Pharmaceutical Company, to co-develop and accelerate the deployment of its technology.

Enzyre's flagship product is the EnzyPad system, a portable device that empowers patients to conduct self-tests at home. This system consists of four main components: a blood sampling device, a single-use microfluidic cartridge called the "EnzyCard" pre-loaded with necessary reagents, a reusable tablet-sized processor named the "EnzyPad" that analyzes the sample, and a mobile application for data management. The EnzyCard can simultaneously measure up to sixteen different reactions from a single drop of blood, providing results that are then transferred via Bluetooth to a mobile app and a cloud-based application. This allows for real-time data sharing with healthcare providers, enabling timely and personalized adjustments to treatment, thereby reducing hospital visits and overall healthcare costs. To fund the development, clinical trial registrations, and manufacturing of this platform, Enzyre successfully closed a €12 million Series A financing round in November 2022.